✦ LIBER ✦

Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of radiation therapy oncology group (RTOG) 83-02

✍ Scribed by Kevin J. Murray; Diana F. Nelson; Charles Scott; A.Jennifer Fischbach; Arthur Porter; Nancy Farnan; Walter J. Curran Jr.

Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 809 KB
Volume: 31
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(95)93160-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality adjusted survival analysis of ma

Quality adjusted survival analysis of malignant glioma patients treated with twice-daily radiation (RT) and carmustine: A report of radiation therapy oncology group (RTOG) 83-02

✍ Kevin J. Murray; Diana F. Nelson; Steven Isaacson; Charles Scott; Jennifer A. Fi 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Survival comparison of radiosurgery elig

Survival comparison of radiosurgery eligible and ineligible malignant glioma patients treated with hyperfractionated radiation therapy (RT) and BCNU: a report of radiation therapy oncology group (RTOG) 83-02

✍ W.J. Curran Jr; C.B. Scott; J.S Nelson; L.A. Martin; A.S. Weinstein; T.L. Philli 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Central pathology review in clinical tri

Central pathology review in clinical trials for patients with malignant glioma. A report of radiation therapy oncology group 83-02

✍ Charles B. Scott; James S. Nelson; Nancy C. Farnan; Walter J. Curran Jr.; Kevin 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 617 KB

Final report of a phase I/II trial of hy

Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83-02

✍ Maria Werner-Wasik; Charles B. Scott; Diana F. Nelson; Laurie E. Gaspar; Kevin J 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB

## BACKGROUND. Efforts to improve local control and survival by increasing the dose of once-daily radiation therapy beyond 70 Gray (Gy) for patients with malignant gliomas have as yet been unsuccessful. Hyperfractionated radiation therapy (HF) should allow for delivery of a higher total dose witho